Pyxis Oncology (PYXS) Cash from Financing Activities (2020 - 2025)
Pyxis Oncology (PYXS) posted quarterly Cash from Financing Activities of $669000.0 for Q4 2025, up 1238.0% year-over-year from $50000.0 in Q4 2024, and up 8462.5% quarter-over-quarter from -$8000.0 in Q3 2025.
Pyxis Oncology (PYXS) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Cash from Financing Activities for 6 consecutive years, with $669000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 1238.0% year-over-year to $669000.0; the TTM figure through Dec 2025 stood at $2.4 million (down 96.01% YoY), while the FY2025 annual figure was $594000.0, down 99.0% from the prior year.
- Cash from Financing Activities improved to $669000.0 in Q4 2025 per PYXS's latest filing, from -$8000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $154.9 million in Q4 2021 and bottomed at -$1.7 million in Q3 2021.
- Historically, Cash from Financing Activities has averaged $24.3 million across 5 years, with a median of $50000.0 in 2024.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities soared 15489900.0% — and 2023, when it tumbled 2950.0%.
- Pyxis Oncology's Cash from Financing Activities stood at $154.9 million in 2021, then sank by 100.0% to $6000.0 in 2022, then plunged by 516.67% to -$25000.0 in 2023, then jumped by 300.0% to $50000.0 in 2024, then surged by 1238.0% to $669000.0 in 2025.
- Business Quant data shows PYXS's Cash from Financing Activities at $669000.0 in Q4 2025, -$8000.0 in Q3 2025, and $50000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 669,000.00 |
| Dec 31, 2025 | 669,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Dec 31, 2024 | 50,000.00 |
| Dec 31, 2024 | 50,000.00 |
| Sep 30, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 110,000.00 |
| Jun 30, 2024 | 110,000.00 |
| Mar 31, 2024 | 57.51 Mn |
| Mar 31, 2024 | 57.51 Mn |
| Dec 31, 2023 | -25,000.00 |
| Dec 31, 2023 | -25,000.00 |
| Sep 30, 2023 | -171,000.00 |
| Sep 30, 2023 | -171,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 1,000.00 |